Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MelCancerVac in Advanced NSCLC
NCT00442754Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Dec 2006
- Primary completion
- Nov 2009
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MelCancerVac in non-small cell lung cancer (NSCLC), sponsored by Herlev Hospital. Primary endpoint: Antigen Specific Immunological Reaction at 3 years. Started Dec 2006; status: completed.
02
Drugs
MelCancerVac
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00442754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00442754.